The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review
Pongsakorn Tantilipikorn,Virat Kirtsreesakul,Chaweewan Bunnag,Mukda Vangveeravong,Sanguansak Thanaviratananich,Supinda Chusakul
DOI: https://doi.org/10.2147/jaa.s451733
2024-07-13
Journal of Asthma and Allergy
Abstract:Pongsakorn Tantilipikorn, 1 Virat Kirtsreesakul, 2 Chaweewan Bunnag, 3 Mukda Vangveeravong, 4 Sanguansak Thanaviratananich, 5 Supinda Chusakul 6 1 Center of Research Excellence in Allergy & Immunology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand; 2 Department of Otolaryngology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand; 3 Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 4 Queen Sirikit National Institute of Child Health, Bangkok, Thailand; 5 Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Khonkaen, Thailand; 6 Department of Otolaryngology, Chulalongkorn University, Bangkok, Thailand Correspondence: Virat Kirtsreesakul, Division of Allergy and Rhinology, Department of Otolaryngology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand, Tel/Fax +6674 429-620, Email The incidence of allergic rhinitis (AR) in Asia and the world is steadily rising. Patients experience incomplete symptom relief despite existing treatment options, which warrants the need for new therapeutic regimes. Azelastine hydrochloride/fluticasone propionate (MP-AzeFlu), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate has been indicated in the treatment of AR. The current review discusses the effects of MP-AzeFlu versus conventional therapies in achieving superior clinical improvement with a very rapid onset of action (5 minutes). The superiority of MP-AzeFlu in offering complete symptom control with sustained relief in patients with AR compared to the existing therapeutic options is also discussed. MP-AzeFlu has been shown to improve the quality of life for patients with AR, thereby enhancing patient adherence to therapy and establishing its preference for the treatment of AR. Currently, the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines recommend the use of a combination of intranasal corticosteroids and intranasal antihistamines as first-line treatment in patients with persistent AR with visual analog scores ≥ 5 or when prior treatment with single agents has been ineffective. Widely published data on the efficacy and safety of its prolonged use in adults and children have validated that effective treatment of AR can be achieved with MP-AzeFlu. Keywords: fixed-dose combination, intranasal, MP-AzeFlu, corticosteroids, antihistamines Allergic rhinitis (AR), a highly prevalent chronic disease of the upper airways, has been found to affect over 600 million people worldwide with an increasing global incidence. 1–3 In the Asia-Pacific (APAC) region alone, the prevalence of AR ranges from 10%–50%. 4 Furthermore, 71% of patients experience persistent AR whereas 29% of patients have intermittent AR. 1 Allergic rhinitis is often associated with comorbidities such as asthma, sinusitis, otitis media, atopic dermatitis, conjunctivitis, and nasal polyposis. 5,6 While most patients with asthma also have rhinitis, asthma is reported in 10%–40% of patients with AR. 7,8 In patients with asthma and co-morbid AR, underdiagnosis or undertreatment of AR could worsen asthma treatment outcomes. 4 The annual medical costs associated with the management and treatment of AR are high. The indirect costs associated with reduced work productivity have been reported to be higher among AR patients compared to those incurred by patients with asthma. 7,9 MP-AzeFlu, a fixed-dose combination (FDC) of azelastine hydrochloride (AZE) and fluticasone propionate (FP) delivered via one device, is indicated for control of AR-related nasal and ocular symptoms. 10 MP-AzeFlu has an onset of action of 5 minutes, which is comparatively less than those of standard pharmacotherapeutic agents (oral antihistamines [OAH] or intranasal corticosteroids/[INCS]) used as mono- or multiple therapies. 10 Based on the tolerability and effect on AR control, the use of this FDC as an advanced alternative in the treatment of AR has been suggested. 11 Studies have also evaluated MP-AzeFlu in terms of total AR-related treatment costs including medical and pharmacy costs when compared to standard therapeutic agents. 11,12 In this review, we consolidate and assess evidence regarding the clinical efficacy and safety of MP-Aze Flu in resolving AR symptoms and elaborate on its effects on overall symptom relief in patients. Furthermore, we discuss its effect on QoL and patient satisfaction in comparison with standard-of–care medications approved in Asia. The positioning of MP-AzeFlu as a potential candidate for inclusion in the essential drug list i -Abstract Truncated-
immunology,allergy,respiratory system